drugset / Trial / NCT01230125

Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery

NCT01230125

Phase 3 Completed 311 enrolled Bausch & Lomb Incorporated
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.

Timeline

Start
2010-11
Primary completion
2011-06
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Mapracorat Small molecule 3 % Other

Indications